TORONTO, ONTARIO -- (Marketwired) -- 02/12/16 -- BioSyent Inc. ("BioSyent") (TSX VENTURE: RX)(OTC PINK: BIOYF) will be reporting its financial results for the fourth quarter and fiscal year ending December 31, 2015 on Friday, March 4, 2016. A presentation on the Company's fourth quarter 2015 results by Rene Goehrum, BioSyent President and CEO, will also be available on the Company's website on the date of release.
The Company also wishes to announce that its Board of Directors has passed a resolution to grant a total of 45,201 stock options to employees, management, officers and directors of BioSyent. The option grant is the result of BioSyent's annual compensation review and is made under the Company's Incentive Stock Option Plan ("the Plan") approved by shareholders on June 12, 2015. Each option entitles the optionee to purchase one common share of the Company at an exercise price of $6.20. These options are excerciseable for a period of ten years from the date of grant.
In addition, the Board of Directors has approved the granting of up to an additional 1,187 options under the Plan to be issued to future new employees of the Company. If granted, the vesting schedule and the exercise price of such options will be determined in accordance with the terms of the Plan and the policies of the TSX Venture Exchange on the date of grant.
About BioSyent Inc.
Listed on the TSX Venture Exchange under the trading symbol "RX", BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, hospital and international business units.
As of the date of this press release, the Company has 14,021,195 shares issued and outstanding.
For a direct market quote (15 minutes delay) for the TSX Venture Exchange and other Company financial information please visit www.tmxmoney.com.
Contacts:
Mr. René C. Goehrum
President and CEO
BioSyent Inc.
(905) 206-0013
investors@biosyent.com
www.biosyent.com
